首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection
【24h】

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection

机译:白介素28B基因变异对慢性丙型肝炎病毒1型双重感染联合治疗结局的综合影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In patients with chronic hepatitis C virus (HCV) infection, several variants of the interleukin-28B (IL28B) gene have been shown to correlate significantly with a sustained virologic response (SVR). Recent evidence shows that determination of one single IL28B polymorphism, rs12979860, is sufficient for predicting treatment outcome. We examined whether the combined determination of the IL28B single-nucleotide polymorphisms (SNPs), rs12979860, rs8099917, rs12980275, and rs8103142, might improve the prediction of SVR in patients with HCV. In the study cohort, 54% of 942 patients with chronic HCV type 1 infection had SVR. The IL28B SNPs, rs12979860CC and rs8099917TT, correlated significantly with SVR (68% and 62%). The SNPs, rs12980275 and rs8103142, were in strong linkage disequilibrium with rs12979860 and were not included in further analysis. In homozygous carriers of the rs12979860 responder allele C, additional genotyping of the rs8099917 SNP had no effect on response prediction, whereas in carriers of the rs12979860 nonresponder allele, the rs8099917 SNP improved the response prediction. In heterozygous carriers of the rs12979860 nonresponder T allele, SVR rates were 55% in the presence of the rs8099917TT genotype and 40% in patients carrying the rs8099917 TG or GG genotype. Analysis of an independent confirmation cohort of 377 HCV type 1-infected patients verified the significant difference in SVR rates between the combined genotypes, rs12979860CT/rs8099917TT and rs12979860CT/rs8099917TG (38% versus 21%; P = 0.018). Conclusion: Treatment outcome prediction could not be improved in homozygous carriers of the IL28B rs12979860 C responder allele by the additional determination of the rs8099917 SNP. There is evidence that a significant proportion of heterozygous carriers of the rs12979860 T nonresponder allele can profit with respect to SVR prediction by further determination of the rs8099917 SNP.
机译:在慢性丙型肝炎病毒(HCV)感染的患者中,白介素28B(IL28B)基因的几种变体已显示出与持续的病毒学应答(SVR)显着相关。最近的证据表明,确定一种IL28B多态性rs12979860足以预测治疗结果。我们检查了联合测定IL28B单核苷酸多态性(SNP),rs12979860,rs8099917,rs12980275和rs8103142是否可以改善HCV患者的SVR预测。在该研究队列中,942例慢性1型HCV感染患者中有54%患有SVR。 IL28B SNP rs12979860CC和rs8099917TT与SVR显着相关(分别为68%和62%)。 SNP rs12980275和rs8103142与rs12979860处于强烈连锁不平衡状态,因此未包含在进一步的分析中。在rs12979860应答者等位基因C的纯合子携带者中,rs8099917 SNP的其他基因分型对应答预测没有影响,而在rs12979860无应答者等位基因的携带者中,rs8099917 SNP改善了应答预测。在rs12979860无反应性T等位基因的杂合子携带者中,存在rs8099917TT基因型时SVR率为55%,而携带rs8099917 TG或GG基因型的患者中SVR率为40%。对377名1型HCV感染患者的独立确认队列的分析证实,组合基因型rs12979860CT / rs8099917TT和rs12979860CT / rs8099917TG之间的SVR率有显着差异(38%对21%; P = 0.018)。结论:通过额外测定rs8099917 SNP,不能改善IL28B rs12979860 C应答者等位基因纯合子携带者的治疗结果预测。有证据表明,通过进一步确定rs8099917 SNP,大部分rs12979860 T无应答等位基因杂合子携带者可以从SVR预测中获利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号